Suzanne Trudel

12.8k total citations
248 papers, 5.2k citations indexed

About

Suzanne Trudel is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Suzanne Trudel has authored 248 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 202 papers in Hematology, 141 papers in Molecular Biology and 107 papers in Oncology. Recurrent topics in Suzanne Trudel's work include Multiple Myeloma Research and Treatments (194 papers), Protein Degradation and Inhibitors (71 papers) and Peptidase Inhibition and Analysis (43 papers). Suzanne Trudel is often cited by papers focused on Multiple Myeloma Research and Treatments (194 papers), Protein Degradation and Inhibitors (71 papers) and Peptidase Inhibition and Analysis (43 papers). Suzanne Trudel collaborates with scholars based in Canada, United States and Spain. Suzanne Trudel's co-authors include Donna Reece, A. Keith Stewart, Vishal Kukreti, Christine Chen, Zhihua Li, Rodger E. Tiedemann, Joseph Mıkhael, Hong Chang, Esther Masih‐Khan and Sergio Grinstein and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Nature Communications.

In The Last Decade

Suzanne Trudel

227 papers receiving 5.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Suzanne Trudel Canada	40	3.4k	3.0k	2.3k	560	558	248	5.2k
Marc S. Raab Germany	38	3.4k 1.0×	3.5k 1.2×	2.4k 1.0×	736 1.3×	519 0.9×	201	5.5k
Andrzej Jakubowiak United States	43	4.2k 1.2×	4.1k 1.3×	3.1k 1.3×	552 1.0×	454 0.8×	262	6.3k
Lori Hazlehurst United States	35	2.5k 0.7×	1.7k 0.6×	1.9k 0.8×	575 1.0×	473 0.8×	91	4.6k
Enrique M. Ocio Spain	41	2.7k 0.8×	2.6k 0.9×	1.9k 0.8×	834 1.5×	1.4k 2.5×	206	5.2k
Sonia Vallet United States	31	1.8k 0.5×	1.4k 0.4×	1.5k 0.6×	345 0.6×	322 0.6×	104	3.3k
Laurence Catley United States	30	2.9k 0.8×	2.3k 0.7×	1.4k 0.6×	519 0.9×	436 0.8×	59	4.0k
Alexander E. Perl United States	37	3.2k 0.9×	3.9k 1.3×	942 0.4×	488 0.9×	1.6k 2.8×	200	6.3k
Güllü Görgün United States	31	1.7k 0.5×	1.5k 0.5×	1.4k 0.6×	1.4k 2.4×	894 1.6×	74	3.8k
Kenneth H. Shain United States	26	1.7k 0.5×	1.2k 0.4×	1.7k 0.7×	918 1.6×	378 0.7×	144	3.4k
Kimberly Stegmaier United States	38	3.6k 1.1×	1.2k 0.4×	1.0k 0.4×	403 0.7×	368 0.7×	135	5.4k

Countries citing papers authored by Suzanne Trudel

Since Specialization

Citations

This map shows the geographic impact of Suzanne Trudel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne Trudel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne Trudel more than expected).

Fields of papers citing papers by Suzanne Trudel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne Trudel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne Trudel. The network helps show where Suzanne Trudel may publish in the future.

Co-authorship network of co-authors of Suzanne Trudel

This figure shows the co-authorship network connecting the top 25 collaborators of Suzanne Trudel. A scholar is included among the top collaborators of Suzanne Trudel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suzanne Trudel. Suzanne Trudel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Touzeau, Cyrille, Hanlon Sia, Sebastian Grosicki, et al.. (2025). Impact of tumor burden on the risk of cytokine release syndrome (CRS) in patients with multiple myeloma treated with elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) in the MagnetisMM-6 trial. Blood. 146(Supplement 1). 2283–2283.

Terpos, Evangelos, Suzanne Trudel, María‐Victoria Mateos, et al.. (2025). Practical Guidance on Clinical Management of Belantamab Mafodotin‐Associated Ocular Events. American Journal of Hematology. 100(10). 1839–1850. 2 indexed citations

Campos, Cecília Bonolo de, Zhihua Li, Michael St. Paul, et al.. (2025). Autophagy/lysosome disruption via pikfyve inhibition in multiple myeloma. Blood. 146(Supplement 1). 3316–3316.

Trudel, Suzanne, Hang Quach, Luděk Pour, et al.. (2025). Elranatamab in Combination With Daratumumab and Lenalidomide (EDR) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant: Initial Results from MagnetisMM-6 Part 1. Clinical Lymphoma Myeloma & Leukemia. 25. S5–S5.

Vesole, David H., Thomas G Martin, Suzanne Trudel, et al.. (2024). Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM). Blood. 144(Supplement 1). 1982–1982. 1 indexed citations

Devasia, Anup J., Esther Masih‐Khan, Jing Yang, et al.. (2024). Incidence and Severity of Hypogammaglobulinemia, and Profile of Infections in Patients with Relapsed Multiple Myeloma Treated with Belantamab Mafodotin. Blood. 144(Supplement 1). 3787–3787. 1 indexed citations

McCurdy, Arleigh, Donna Reece, Martha Louzada, et al.. (2024). Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial. Blood Cancer Journal. 14(1). 155–155. 2 indexed citations

Croucher, Danielle, Anup J. Devasia, Zhihua Li, et al.. (2023). Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression. Molecular Case Studies. 9(2). a006249–a006249. 5 indexed citations

Bahlis, Nizar J., Caitlin Costello, Noopur Raje, et al.. (2023). Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nature Medicine. 29(10). 2570–2576. 76 indexed citations

10.

Lajkosz, Katherine, Esther Masih‐Khan, Donna Reece, et al.. (2023). The Impact of CD34+ Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 23(11). 850–856. 2 indexed citations

11.

Vesole, David H., Jesús G. Berdeja, Jeffrey Matous, et al.. (2023). P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.. HemaSphere. 7(S3). e5189693–e5189693.

12.

Stewart, A. Keith, et al.. (2021). PIK-001 a Novel Small Molecule Inhibitor of Pikfyve for Treatment of Multiple Myeloma (MM). Blood. 138(Supplement 1). 1602–1602. 1 indexed citations

13.

Medaglia, Alice Annalisa, Ajay K. Nooka, Nizar J. Bahlis, et al.. (2020). Dreamm-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (rrmm). SHILAP Revista de lepidopterología. 1 indexed citations

14.

Yang, Jing, Haiyan Jiang, Esther Masih‐Khan, et al.. (2017). Tolerability and Efficacy of Post Transplant Lenalidomide Maintenance Therapy in Multiple Myeloma: A Real World Single Centre Experience. Blood. 130. 3462–3462. 5 indexed citations

15.

Reece, Donna, Esther Masih‐Khan, Eshetu G. Atenafu, et al.. (2017). Real World Outcomes of Newly Diagnosed High-Risk Multiple Myeloma Patients Treated at Princess Margaret Cancer Centre: A Retrospective Chart Review. Blood. 130. 2010–2010. 1 indexed citations

16.

Pandyra, Aleksandra A., Peter Mullen, Manpreet Kalkat, et al.. (2014). Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop. Cancer Research. 74(17). 4772–4782. 64 indexed citations

17.

Chen, Christine I., Rodger E. Tiedemann, Suzanne Trudel, et al.. (2013). Induction Therapy With Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) For Primary Plasma Cell Leukemia (pPCL). Blood. 122(21). 5378–5378. 3 indexed citations

18.

Alsina, Melissa, Suzanne Trudel, Richard R. Furman, et al.. (2012). A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma. Clinical Cancer Research. 18(17). 4830–4840. 119 indexed citations

19.

Liang, Sheng-Ben, Young Trieu, Zhihua Li, et al.. (2011). Molecular Target Characterization and Antimyeloma Activity of the Novel, Insulin-like Growth Factor 1 Receptor Inhibitor, GTx-134. Clinical Cancer Research. 17(14). 4693–4704. 8 indexed citations

20.

Reece, Donna, Christine Chen, Suzanne Trudel, et al.. (2008). Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma. Journal of Clinical Oncology. 26(29). 4777–4783. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact